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Abstract The very low density lipoprotein receptor is a member
of the low density lipoprotein receptor supergene family for
which two isoforms have been reported, one lacking and the other
containing an O-linked sugar domain. In order to gain insight
into their functionality, transient and stable transformants
separately overexpressing previously cloned bovine variants were
analyzed. We report evidence that the variant lacking the O-
linked sugar domain presented a rapid cleavage from the cell and
that a large amino-terminal very low density lipoprotein receptor
fragment was released into the culture medium. As only minor
proteolysis was involved in the other very low density lipoprotein
receptor variant, the clustered O-linked sugar domain may be
responsible for blocking the access to the protease-sensitive
site(s). To test this hypothesis, a mutant Chinese hamster ovary
cell line, ldlD, with a reversible defect in the protein O-
glycosylation, was used. The instability of the O-linked sugar-
deficient very low density lipoprotein receptor on the cell surface
was comparable to that induced by the proteolysis of the variant
lacking the O-linked sugar domain. Moreover, our data suggest
that the O-linked sugar domain may also protect the very low
density lipoprotein receptor against unspecific proteolysis. Taken
together, these results indicate that the presence of the O-linked
sugar domain may be required for the stable expression of the
very low density lipoprotein receptor on the cell surface and its
absence may be required for release of the receptor to the
extracellular space. The exclusive expression of the variant
lacking the O-linked sugar domain in the bovine aortic
endothelium opens new perspectives in the physiological sig-
nificance of the very low density lipoprotein receptor.
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1. Introduction
The very low density lipoprotein (VLDL) receptor is a
membrane glycoprotein present in two isoforms whose phys-
iological function has not yet been established. It is a member
of the low density lipoprotein (LDL) receptor supergene fam-
ily and is structurally related to the LDL receptor. Five func-
tional domains have been de¢ned, corresponding to di¡erent
exons in the gene: (i) a ligand-binding domain composed of
multiple cysteine-rich repeats, (ii) an epidermal growth factor
precursor homologous domain, (iii) a highly O-glycosylated
domain, (iv) a short transmembrane domain and (v) a cyto-
plasmic domain with a coated pit targeting signal. The O-
linked sugar domain is a serine/threonine-rich domain close
to the cell membrane that corresponds to exon 16 in the gene
and can be di¡erentially spliced in humans, rats, rabbits and
bovines [1^5], but not in mice [6]. The VLDL receptor is
modi¢ed by asparagine-linked (N-linked) glycosylation and
most of the mucin-type serine/threonine-linked (O-linked) oli-
gosaccharides are bonded to the O-linked sugar domain. This
clustered O-linked sugar domain is analogous to that in the
LDL receptor [7] and decay accelerating factor [8]. The VLDL
receptor is a multiligand receptor. The mammalian receptor
shows a⁄nity for several ligands, including receptor-associ-
ated protein (RAP) [9^11], apoE-containing lipoproteins
[12^17], lipoprotein lipase [18], serine proteinase/serpin com-
plexes [18^20], lipoprotein Lp(A) [21] and the minor group of
human rhinoviruses [22]. No di¡erences in the ligand speci¢c-
ity or intracellular processing have been found between the
two VLDL receptor variants.
The predominant sites of VLDL receptor expression in all
mammals have been found in extrahepatic organs like heart,
skeletal muscle and adipose tissue [12,23^26]. The relative ex-
pression levels of the two VLDL receptor variants in di¡erent
tissues has not been analyzed in detail. However, recent stud-
ies show that both variants are expressed in certain human,
rabbit and bovine tissues [24,4,5], whereas the variant lacking
exon 16 is a major component in the white matter of human
brain [27], in some rabbit non-muscle tissues [4] and in the
bovine kidney, liver and mammary gland [5]. Cell-speci¢c ex-
pression of the variant lacking the O-linked sugar domain has
been demonstrated for epithelial cells from breast carcinomas
[28], for endothelial cells from bovine aortas [5] and for the
growing oocyte in the chicken homologue of the VLDL re-
ceptor [29]. Expression of VLDL receptor variants is cell- and
tissue-speci¢c and, thus, their role or regulation could be dif-
ferent
We have recently cloned the bovine VLDL receptor var-
iants, the one lacking and the other containing the O-linked
sugar domain [5]. We studied the expression of these variants
in three di¡erent cell lines, one of them with stable overex-
pression, and using a mutant Chinese hamster ovary (CHO)
cell line, ldlD, with a reversible defect in the addition of ga-
lactose (Gal) and N-acetylgalactosamine (GalNAc) to oligo-
saccharide chains of glycoproteins [30]. All the results indicate
that the presence or absence of clustered O-linked sugar
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chains may be crucial to VLDL receptor stability or release to
the extracellular space.
2. Materials and methods
2.1. Materials
FITC-conjugated and peroxidase-conjugated swine anti-rabbit were
obtained from Dako (Santa Barbara, CA, USA). The antibody
against the amino-terminal 160 amino acids of the human VLDL
receptor was as previously described [31]. Rabbit polyclonal antibod-
ies against the 20 amino acids carboxyl-terminal domain of the hu-
man, rabbit and mouse VLDL receptors were as described [32]. RAP
and polyclonal antibodies against the recombinant RAP protein were
prepared as described elsewhere [33]. UDP-Gal/UDP-GalNAc 4-epi-
merase-de¢cient mutant (ldlD) CHO cells were described previously
[30]. Cell culture reagents were from Whittaker (Walkersville, MD,
USA). All other chemicals were of analytical grade.
2.2. Cell culture and transfection experiments
Bovine VLDL receptor cDNA variants ([5], GenBank accession
Fig. 1. Immuno£uorescence studies of VLDL receptors on transfected COS1 cells. COS1 cells were transfected with a vector encoding the bo-
vine VLDL receptor variant either containing (A, B) or lacking (C, D) the O-linked sugar domain and processed 48 h later. To detect the in-
tracellular pattern of the VLDL receptor (A, C), cells were processed as described in Section 2. The cell surface pattern of expression was de-
tected on ¢xed cells (B, D) using the same primary and secondary antibodies. Film exposure times: 1 min for A, B and C, 2 min for D. Bar:
30 Wm. VLDL receptor immunodetection in permeabilized and non-permeabilized COS1 cells transfected with bovine VLDL receptor cDNAs
(E). Percentages of labelled cells refer to the number of cells overexpressing the VLDL receptor out of the total number of cells counted. The
mean of three independent experiments is shown. Di¡erences between the triplicates were less than 4%.
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numbers are AF016537 and AF034420) were separately subcloned
into the pCR3.1 vector (Invitrogen, Groningen, The Netherlands).
COS1 cells, used for transfection experiments, were cultured in
Dulbecco’s modi¢ed Eagle’s medium (DMEM), with 4.5 g/l glucose
and 10% fetal bovine serum. Transient transfection experiments were
performed as described [34].
MDCK cells were cultured in DMEM, with 1.0 g/l glucose and 10%
fetal bovine serum. Plasmids encoding the bovine VLDL receptor
variants were separately introduced to MDCK cells using lipofect-
amine reagent (Life Technologies, Gaithersburg, MD, USA) as rec-
ommended by the manufacturer. Stable transformants were selected in
600 Wg/ml active G418 (Life Technologies). G418-resistant clones were
isolated using cloning rings and screened for VLDL receptor expres-
sion by immuno£uorescent staining and Western blot. 14 positive
clones were found. The colonies transfected with the bovine VLDL
receptor variant lacking or containing the O-linked sugar domain are
designated in this study as #m or #p, respectively.
Wild-type CHO cells (CHO-K1) and ldlD cells were grown in
Ham’s F-12 medium with 5% fetal calf serum, 100 U/ml penicillin,
10 Wg/ml streptomycin and 2 mM glutamine. 20 WM Gal was added to
ldlD cells culture medium to allow synthesis of glycoproteins with
normal N-linked oligosaccharides [35].
2.3. Western and ligand blotting analyses
Media were collected from cells after 2 days without changing the
medium. Intact cells were removed from the medium by centrifuga-
tion at 1000 rpm in an Omnifuge 2.0 RS Heraeus centrifuge for 5 min
at 4‡C.
Cell extracts were prepared from cells grown to con£uence in
60 mm dishes. Cells were scraped into a solution that contained
50 mM Tris (pH 7.4), 2 mM EDTA, 150 mM NaCl, 1% Igepal Ca-
630, 0.4% sodium deoxycholate, 0.4% SDS and 1 mM PMSF. The
extracts were passed through a syringe provided with a 0.9 mmU40
mm needle and used for electrophoresis and Western blot.
To study cell surface expression of the VLDL receptor, cells were
pre-treated with trypsin-EDTA solution (Whittaker) for di¡erent
times at 37‡C and then, cell extracts were obtained.
Samples were run on 7.5% SDS-polyacrylamide gels under reducing
conditions. VLDL receptor was immuno-detected with antibodies
against the N-terminal domain or against the C-terminal domain.
The immunoreaction was visualized by a chemiluminescence system
(Amersham). For RAP ligand blotting, the samples were run on 7.5%
SDS-PAGE under non-reducing conditions. The nitrocellulose mem-
branes were incubated with 25 nM RAP in 10 mM Tris (pH 7.4)
containing 3% not-fat milk, 0.02% Tween-20 and 5 mM CaCl2, over-
night at 4‡C. Filters were then incubated with a rabbit anti-RAP IgG.
2.4. Immuno£uorescence microscopy
For immuno£uorescence studies, cells were grown on coverslips
and, after washing, ¢xed with 3% paraformaldehyde in 0.1 M phos-
phate bu¡er pH 7.4 containing 60 mM sucrose. To detect cell surface
VLDL receptor, cells were incubated at 37‡C for 45 min with anti-
bodies against the N-terminal domain of the human VLDL receptor.
To detect the intracellular pattern, cells were previously permeabilized
with 0.1% Triton X-100. Both cell preparations were then processed
for immuno£uorescence as described [34] with FITC-conjugated swine
anti-rabbit immunoglobulins to detect the VLDL receptor. The di¡er-
ent percentages of labelled cells were obtained by counting more than
500 cells in each of the three independent experiments.
3. Results
In order to gain insight into the functionality of previously
described bovine VLDL receptor variants [5], we transfected
COS1 cells with expression vectors separately containing these
variant forms. The intracellular pattern in permeabilized cells
was the same for both variants (Fig. 1A and C), suggesting
that they were equally processed. Although the cell surface
VLDL receptor showed a similar punctate pattern in both
variants (Fig. 1B and D), cells transfected with the bovine
VLDL receptor lacking the O-linked sugar domain showed
a lower £uorescent intensity (compare Fig. 1B, exposure
time 1 min, with Fig. 1D, exposure time 2 min). The e⁄ciency
of transfection with both variants was the same as they pre-
sented similar percentage values when intracellular expression
of transfected cells was considered (Fig. 1E). In addition, the
percentage of cells overexpressing the receptor lacking the O-
linked sugar domain on the cell surface was less than half that
of the variant containing the O-linked sugar domain (Fig. 1E).
As the antibodies against the N-terminal domain recognize
Fig. 2. Blot analysis of VLDL receptor in cell extracts and media
from transfected COS1 cells and stable MDCK cell lines. A: Mem-
branes and media of COS1 cells transiently overexpressing the bo-
vine VLDL receptor variant either lacking (m) or containing (p) the
O-linked sugar domain. B: Cell extracts and media of two MDCK
clones stably overexpressing the bovine VLDL receptor form either
lacking (#m) or containing (#p) the O-linked sugar domain. Sam-
ples were size-fractioned on a 7.5% SDS-polyacrylamide gel under
either non-reducing conditions (RAP ligand blotting: upper panels)
or reducing conditions (Western blotting: middle and lower panels),
electrophoretically transferred to a nitrocellulose ¢lter and incubated
with 25 nM RAP followed by anti-RAP IgG or N-terminal antibod-
ies against the VLDL receptor or C-terminal antibodies, as indi-
cated. 30 Wg of protein from cell extracts and 50 Wl of medium were
loaded to each lane.
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both variants, the variant lacking the O-linked sugar domain
may present an anomalous cell surface expression.
Membrane extracts and media from COS1 cells transiently
and separately overexpressing both variants were obtained
and subjected to RAP ligand blotting assays and Western
blotting using the antibodies against the N-terminal domain
of the human VLDL receptor and against the C-terminal
domain of the protein. As shown in Fig. 2A (upper panel),
RAP bound to 105 kDa and 120 kDa proteins from the mem-
brane extracts that corresponded, respectively, to bovine
VLDL receptor variants lacking and containing the O-linked
sugar domain. In Western blotting assays (Fig. 2A, middle
and lower panel), a 118 kDa band which corresponded to
the bovine VLDL receptor lacking the O-linked sugar domain
was immuno-detected. This band could correspond to both
the precursor and mature form of the receptor because of
the small di¡erence in molecular weight between them. The
145 kDa and 127 kDa proteins could be, respectively, the
mature and the precursor form for the bovine VLDL receptor
containing the O-linked sugar domain. RAP also bound to a
94 kDa protein in medium from cells overexpressing the var-
iant lacking the O-linked sugar domain, which was also im-
muno-detected by the antibodies against the N-terminal do-
main (108 kDa under reducing conditions), but not with the
C-terminal antibodies (Fig. 2A). This VLDL receptor product
was 11 kDa shorter than the receptor from the cell extracts
and it was hardly detectable in medium from cells overex-
pressing the variant containing the O-linked sugar domain
(107 kDa band, only in RAP ligand blotting assays). The
other band of 124 kDa that appeared in media (Fig. 2A,
upper panel) was non-speci¢c as it was also detected in con-
trol ¢lters incubated with only anti-RAP IgG, but not with
N-terminal antibodies.
To extent these analyses to a di¡erent cell line, stable
MDCK transformants separately overexpressing one of the
variants were selected and isolated. In all positive clones an-
alyzed, the same bands described above for the cell extracts
were detected by RAP ligand blotting assays and Western
blotting using the antibodies against the N-terminal domain
and against the C-terminal domain of the protein (Fig. 2B).
The 88 kDa band which was detected in some cell extracts by
RAP blotting assays (Fig. 2B, upper panel) was non-speci¢c
as it also appeared in control ¢lters incubated with only anti-
RAP IgG, but not in Western blotting assays. These results
suggest that the VLDL receptor lacking the O-linked sugar
domain is proteolized and that the cutting site should be
closed to the membrane-spanning domain of the protein.
Thus, two products were given in the variant lacking the
O-linked sugar domain, a 94 kDa product (108 kDa under
reducing conditions), which was released into the medium,
and a 11 kDa product, which contained the transmembrane
and the cytoplasmic domain of the bovine VLDL receptor.
The 107 kDa band could be a consequence of a similar, but
much less extensive, proteolysis/release of the receptor con-
taining the O-linked sugar domain.
To study the sensitivity to extracellular proteolysis of the
bovine VLDL receptor on the cell surface, two di¡erent stable
MDCK clones were treated with trypsin-EDTA for increasing
times at 37‡C and their homogenate extracts were analyzed by
Western blotting (Fig. 3). Trypsin unspeci¢cally cuts the ex-
tracellular domain of the bovine VLDL receptor at more than
70 sites [5]. After trypsin-EDTA treatment, the amount of
VLDL receptor lacking the O-linked sugar domain decreased
markedly in cell extracts. In contrast, the e¡ect of this pro-
teolysis on the VLDL receptor containing the O-linked sugar
domain was much lower. Although some surface receptors
were proteolyzed, the O-linked sugar domain still conferred
some protection, as 92 kDa and 86 kDa forms of the receptor
were found. These proteins were produced by the proteolytic
removal of a fragment from the N-terminus of the mature
receptor, as they were detected by the antibodies against the
C-terminal domain of the protein (Fig. 3), but not against the
N-terminal domain (data not shown).
To analyse the function of the O-linked sugar domain on
the VLDL receptor, we compared VLDL receptor expression
in wild-type CHO cells and in a mutant CHO cell line, a
Fig. 3. The e¡ect of trypsin-EDTA treatment on VLDL receptor
variants. Two MDCK clones stably overexpressing the bovine
VLDL receptor form either lacking (#m) or containing (#p) the O-
linked sugar domain were used. Cells were incubated with trypsin-
EDTA for increasing times at 37‡C. Homogenates were obtained,
size-fractioned by SDS-PAGE under reducing conditions and sub-
jected to Western blotting with antibodies against the C-terminal
domain of the VLDL receptor. 30 Wg of protein was loaded to each
lane.
Fig. 4. VLDL receptor studies on ldlD cells. Wild-type CHO or
ldlD cells were transfected with the VLDL receptor variant either
lacking (m) or containing (p) the O-linked sugar domain. Cells were
grown in a medium that contained the following: no additions (0),
Gal at 20 WM or both Gal and GalNAc (at 200 WM). At 48 h post-
transfection, homogenates and media were obtained and trypsin-
EDTA treatment was performed. Proteins were separated by SDS-
PAGE and subjected to Western blotting with the N-terminal anti-
bodies against the VLDL receptor or the C-terminal antibodies, as
indicated. 30 Wg of homogenate protein and 50 Wl of medium were
loaded to each lane.
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UDP-Gal/UDP-GalNAc 4-epimerase-de¢cient mutant (ldlD)
[30]. ldlD cells have a defect in protein O-glycosylation that
can be rapidly reverted by addition of GalNAc to Gal-sup-
plemented culture medium [35].
To examine the e¡ects of preventing O-glycosylation on
VLDL receptors, wild-type CHO and ldlD cells were trans-
fected with expression vectors encoding bovine VLDL recep-
tor variants lacking or containing the O-linked sugar domain.
Homogenate extracts and media were obtained and analyzed
by Western blotting using the antibodies against the N-termi-
nal domain of the protein. High levels of receptor were ex-
pressed in both ldlD and wild-type CHO cells (Fig. 4, upper
panel). No band corresponding to the VLDL receptor was
seen in blots from untransfected ldlD or wild-type CHO cells
(data not shown). The electrophoretic mobilities observed for
the VLDL receptor in CHO cells were similar to those ob-
served in MDCK clones. The small di¡erences may be due to
changes in the sugars added to the receptor, as described
previously for the human and CHO LDL receptors [36]. A
precursor/mature protein of 118 kDa corresponded to the
VLDL receptor variant lacking the O-linked sugar domain.
The variant containing the O-linked sugar domain was syn-
thesized as a 123 kDa precursor and a 132 kDa mature pro-
tein. In the absence of added GalNAc, ldlD cells normally
synthesized the 118 kDa and 123 kDa precursors but failed
to process them to the mature form (Fig. 4, upper panel). The
electrophoretic mobility of the O-linked sugar-de¢cient VLDL
receptors (Od VLDL receptors) only decreased in the variant
containing the O-linked sugar domain (Fig. 4, upper panel).
A VLDL receptor degradation product was mainly present
in media from those ldlD and wild-type CHO cells which had
VLDL receptors lacking the O-linked sugar domain (108 kDa
band: Fig. 4, middle panel) or Od VLDL receptors (117 kDa
band: Fig. 4, middle panel). This VLDL receptor degradation
product was only detected with the antibodies against the
N-terminal domain of the protein but not against the C-ter-
minal domain (data not shown). Although much less exten-
sive, some proteolysis/release of receptors with normal
O-linked chains also occurred (Fig. 4, middle panel). There-
fore, the VLDL receptor only showed protection against pro-
teolysis in ldlD cells transfected with the bovine variant con-
taining the O-linked sugar domain and grown in the presence
of Gal and GalNAc. These data indicate that the clustered O-
linked sugars are required for the stable expression of VLDL
receptor in ldlD cells.
The role of O-glycosylation of VLDL receptor in ldlD or
wild-type CHO cells in the absence or presence of exogenously
added sugars was analyzed by sensitivity to extracellular di-
gestion with trypsin-EDTA (Fig. 4, lower panel). Homogenate
extracts were examined by Western blotting using the anti-
bodies against the C-terminal domain of the protein. The
e¡ect of trypsin digestion on VLDL receptor variants was
similar to that described for MDCK clones in Fig. 3. After
trypsin-EDTA treatment, the amount of VLDL receptors
lacking the O-linked sugar domain or Od receptors markedly
decreased. Only in cells transfected with the VLDL receptor
variant containing the O-linked sugar domain, and with the
O-glycosylation defect fully reversed, was the e¡ect of trypsin
proteolysis lower. Although some surface receptors were pro-
teolyzed in these cells, the O-linked sugar domain still pro-
tected them, as partially degraded receptors were found (92
kDa and 86 kDa bands: Fig. 4, lower panel). These partially
degraded receptors were a consequence of the proteolytic re-
moval of an N-terminal fragment from the mature receptor,
as they were only immuno-detected with the antibodies
against the C-terminal domain of the protein, but not against
the N-terminal domain (data not shown).
4. Discussion
Previous studies [37] have shown that deletion of the clus-
tered O-linked sugar domain of the human LDL receptor does
not a¡ect the normal stability or function of these receptors.
The O-linked sugars required for the maintenance of LDL
receptor stability are the sugars dispersed on the receptor itself
[38]. The VLDL receptor variants have three dispersed poten-
tial N-linked glycosylation sites and clustered O-linked chains
in the variant containing the O-linked sugar domain. Previous
studies of O-glycosylation of many other glycoproteins have
shown that O-linked sugars play important roles in determin-
ing the receptor stability and function [30,38^41]. Here, we
demonstrate that the presence of the clustered O-linked sugar
domain may be required for the stablility of the VLDL re-
ceptor on the cell surface. The physiological implications of
the presence of a VLDL receptor variant lacking the O-linked
sugar domain require further study.
We showed that the receptor lacking the O-linked sugar
domain presented a rapid cleavage/release from the cell.
This proteolysis occurred on the extracellular part of the re-
ceptor, near the membrane-spanning domain. It is still un-
known how this mechanism takes place. As only minor pro-
teolysis was involved in the VLDL receptor containing the O-
linked sugar domain, we assumed that access to the protease-
sensitive site(s) was prevented by the clustered O-linked sugar
domain. To test this hypothesis, a mutant ldlD CHO cell line,
with a reversible defect in protein O-glycosylation, was used.
No variants in O-glycosylation have been described for cell
surface membrane glycoproteins in the ldlD system. Thus, the
presence of two naturally occurring VLDL receptor variants,
one lacking and the other containing an O-linked sugar do-
main, provides an ideal system to determine the role of the
clustered O-linked sugars. The instability of the O-linked sug-
ar-de¢cient VLDL receptors on the cell surface was compara-
ble to the proteolysis of the variant lacking the O-linked sugar
domain.
The O-linked sugar domain not only prevents cleavage/re-
lease of a large VLDL receptor N-terminal fragment but may
also have protected the receptor against unspeci¢c proteolysis.
After trypsin treatment, an intermediate degradation product
(92^86 kDa) was only recognized in cells overexpressing the
VLDL receptor containing the O-linked sugar domain. Its
electrophoretical mobility suggests that proteolysis may occur
in the multiple cysteine-rich N-terminal region of the receptor.
A degraded form of the CHO LDL receptor has also been
described [36,42] after the removal of an apparently unglyco-
sylated portion of the receptor’s cysteine-rich N-terminus.
The critical role of the O-glycosylation in establishing the
normal surface glycoprotein stability and function has already
been described [30,38^41]. Our ¢ndings are consistent with
those observed for various O-glycosylated cell surface mem-
brane glycoproteins analyzed to date. In four cases, inhibition
of O-glycosylation markedly reduced the amount of these
proteins on the cell surface. In three of these cases, the
LDL receptor [30,38], decay accelerating factor (DAF) [40]
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and the major envelope glycoprotein of the Epstein-Barr virus
[39], rapid proteolytic cleavage after reaching the cell surface
resulted in the release of a large fragment of the extracellular
domains of these proteins. In the case of the interleukin-2
receptor [39], intracellular missorting prevented the O-linked
de¢cient protein from reaching the cell surface. A marked
reduction in cell surface expression of the attachment glyco-
protein of human respiratory syncytial virus [41] and the hu-
man glycophorin A [43] has been found in cells in which both
the N- and O-linked glycosylation is blocked. In contrast,
inhibition of O-glycosylation did not a¡ect either the biosyn-
thesis and secretion of L-amyloid precursor protein [44] or the
sorting, expression and processing of the precursor for trans-
forming growth factor-K [45]. The LDL receptor and DAF
contain an O-linked sugar domain [46,47] at a position anal-
ogous to the VLDL receptor, between the amino-terminal
domain composed of multiple cysteine-rich repeats and the
cell membrane. Naturally occurring variants lacking the
O-linked sugar domain have not been reported for the LDL
receptor and DAF.
The presence in the culture medium of a soluble VLDL
receptor fragment has also been reported for the human
VLDL receptor in other cell-types [4,48]. The role of the large
amino-terminal VLDL receptor fragment released to the me-
dium has not yet been established. However, it has recently
been shown that a homologous VLDL receptor fragment re-
leased from HeLa cells binds to the minor group of human
rhinoviruses (HRV) and inhibits HRV infection [48]. There is
also evidence that a soluble form of the K-chain of the LDL
receptor-related protein is present in normal human plasma
[49] and that a 28 kDa N-terminal fragment of the LDL
receptor is active against vesicular stomatitis virus infection
[50]. Although no soluble form of VLDL receptor has yet
been found in body £uids or the extracellular matrix, the
exclusive expression of a VLDL receptor variant lacking the
O-linked sugar domain in bovine aortic endothelial cells [5]
and, therefore, its potential cleavage/release into the lumen of
the aorta, open new possibilities on the physiological signi¢-
cance of these receptors.
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